NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
Clinical Trials
18 trialsNCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06120491 2026-04-03
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT04484818 2026-03-23
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05794906 2026-03-17
ARASTEP
Bayer
Phase 3 Active not recruiting
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT02799602 2025-12-04
ARASENS
Bayer
Phase 3 Completed
NCT06625970 2025-06-26
PEACE 7
UNICANCER
Phase 3 Recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06276465 2024-12-20
PEACE8
UNICANCER
Phase 3 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT05116475 2024-03-12
ALADDIN
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Recruiting
NCT06177015 2023-12-26
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT04136353 2023-07-28
DASL-HiCaP
University of Sydney
Phase 3 Active not recruiting
NCT04237584 2022-10-07
ESCALATE
MANA RBM
Phase 3 Terminated
NCT02200614 2022-06-28
ARAMIS
Bayer
Phase 3 Completed